Navigation Links
Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
Date:10/20/2011

Dr. LoGrasso was a Research Fellow at Merck Research Laboratories for nearly nine years working in the areas of inflammation and molecular neuroscience. His main research focus was on MAP-kinase signal transduction pathways and associated mechanistic enzymology, inhibitor characterization, and structure-function relationships for MAP kinases.

Dr. LoGrasso received his B.A. in chemistry from New York University in 1985, his M.S. in biochemistry from Florida State University in 1988, and his Ph.D. in pharmacology from the University of Florida in 1992. This was followed by postdoctoral training at the Sandoz Research Institute (now Novartis) working in the area of atherosclerosis and metabolic disease focusing on enzymes in the cholesterol biosynthetic pathway.

Arrien Pharmaceuticals is working for a possible licensing & alliance deals for near term funding for Phase I, II trials and to expand significantly to its value based pipeline. Arrien is seeking collaborations with companies for a number of programs particularly ORS-1006 targeting LRRK2 mediated Parkinson's disease and other CNS indications.

About Arrien Pharmaceuticals & FFDD™

Arrien Pharmaceuticals LLC is a small molecule targeted therapeutics drug discovery and development company working towards targeting cell signaling pathways - A target class in treating Neurodegenerative/CNS, Cancer, Inflammation and Metabolic diseases. Arrien proprietary Fragment-Field Drug Design (FFDD™) Technology typically involves scaffold-based design strategy; extensively implemented by utilizing structural biology data inputs and to assist Medicinal Chemistry in early phase of lead-to-drug-lead identification process. Arrien cost-competent approach assists its technology to influence target-specific leads for multiple protein targets. Moreover, Arrien technology has proven in the identification of potent and highly selective clinical stage candidates.

For fu
'/>"/>

SOURCE Arrien Pharmaceuticals LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arrien Pharmaceuticals Founders closes $2.0 Million Series A Financing
2. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
3. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
4. Amylin Pharmaceuticals Reports Third Quarter Financial Results
5. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
6. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
7. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
8. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
9. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
10. JHP Pharmaceuticals Enters Agreement to Produce Diagnostic Aid
11. Par Pharmaceutical Acquires Three Generic Products From Teva Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... proprietary technology used to develop and produce enzymes ... biopharmaceuticals, and industrial enzymes industries, today announced the ... Bioenergy for commercial scale production of Abengoa,s proprietary ... developed under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... and service provider for the medical industries, announced today the expansion ... New York City . genae Americas was incorporated ... is strategically centered in one of the highest concentrations of medical ... Philippe Kassab , President at genae Americas. "The expansion of genae ...
(Date:10/1/2014)... Oct. 1, 2014  Varian Medical Systems (NYSE: ... results for the fourth quarter of fiscal year 2014 ... 22, 2014.  The news release will be followed by ... p.m. PT.  The news release and a link to ... company website at: www.varian.com/investor .  To access the ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3genae Opens Offices in New York City 2Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2
... , ... Food and Drug Administration (FDA) has notified health professionals, and ... -- from the use of negative pressure wound therapy (NPWT). ... therapy devices can help in the healing and closure of ...
... , ... a leading provider of software solutions to optimize clinical ... release of StudyOptimizer 4, the latest iteration of its ... pharmaceutical companies, DecisionView,s flagship product now includes advanced historical ...
Cached Medicine Technology:Negative Pressure Wound Devices Draw FDA Notice, Advice 2DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... City, NJ (PRWEB) October 01, 2014 Diet ... with their intentions to lose weight and their dieting attempts ... unhealthy, fatty foods. Including hormone diet treatments into ... only allows patients to see fast and effective weight loss ... and begin forming healthy habits to maintain their weight for ...
(Date:10/1/2014)... October 01, 2014 Anti Aging Clinic ... skin rejuvenating destination of choice, is announcing a discounted ... through to December. , “We’re doing this because we ... to our top skin clinic in Toronto,” says Dr. ... so much at Anti Aging Clinic, including laser facials, ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... -- Deadly and difficult to treat, liver cancer has long ... and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration ... of Hepatology that the protein sulfatase 2 (SULF2) may provide ... new therapies. , Mayo Clinic Cancer Center leads the field ...
... Methodist Healthcare -- Memphis,Hospitals ("Methodist") announced today that ... designated maturities of the,Bonds. The tender offer was extended ... April 9, 2008 at 5:00 pm, New York City ... be terminated is applicable to,the following: for the Series ...
... CITY, Calif., April 10 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, Chief,Executive ... 37th,Annual Institutional Unconference on Tuesday, April 15, 2008 ... Atlanta, Georgia., Interested investors are invited to ...
... ANN ARBOR, Mich.---Female penguins mate with males who bring ... gain access to the most productive flowers guarded by ... affluent college students who don,t need resources will still ... Kruger, research scientist at the University of Michigan School ...
... trials could start in several years, study says , , THURSDAY, ... the formation of scar tissue at the site of a ... has been developed by researchers at Northwestern University in Chicago. ... to regrow after a spinal injury, but they,re blocked by ...
... inhibitors exhibit cancer-killing activities in cultured cells. While ... in clinical trials, just how they execute their ... of recent papers, Vanderbilt-Ingram Cancer Center investigators provide ... damage cancer cells and offer clues about possible ...
Cached Medicine News:Health News:Mayo Clinic identifies treatment target for liver cancer recurrence and survival 2Health News:Methodist Healthcare - Memphis Hospitals Announces Termination of Tender Offers 2Health News:Abaxis to Present at the SunTrust Robinson Humphrey's 37th Annual Institutional Unconference 2Health News:Just like penguins and other primates, people trade sex for resources 2Health News:Gel Enables Severed Spinal Cord Fibers to Regrow 2Health News:The good and bad side of anti-cancer compounds 2Health News:The good and bad side of anti-cancer compounds 3
... Strep A Test is a color immunochromatographic ... uses antibody labeled color particles coated at ... DLT allows greater sensitivity than the conventional ... the test procedure, a throat swab is ...
... The IntraLase FS laser introduces new high ... Surgeons now have the opportunity to offer ... to a microkeratome for creating the corneal ... FS laser and proprietary IntraLASIK software, surgeons ...
... Teco Diagnostics manufactures fine urine ... our urine chemistry reagent strips from ... to offer more economical prices compared ... the quality. Teco Diagnostics urine reagent ...
... term complications associated with diabetes continue to ... and quality of life of patients, in ... complications are known to be associated with ... that the level of haemoglobin A1c (HbA1c) ...
Medicine Products: